The STRIDE Study: Concurrent vs Sequential Enzalutamide With Sipuleucel-T for mCRPC

Video

Daniel P. Petrylak, MD, discusses the results of the phase II STRIDE study in metastatic castration-resistant prostate cancer (mCRPC).

Clinical Pearls

Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses the results of thephase II STRIDE studyin metastatic castration-resistant prostate cancer (mCRPC).

  • The STRIDE study evaluated concurrent versus sequential enzalutamide in combination with sipuleucel-T for mCRPC.
  • There was no difference seen in immune parameters when comparing early and delayed enzalutamide. The prime-boost effect was similar in the two arms.
  • Anecdotally, no additive or synergistic toxicities were observed. Full toxicity data will be reported later.
Recent Videos
Related Content
Targeting AML: The Latest Advances

Targeting AML: The Latest Advances

Sabrina Serani
September 20th 2024
Article

Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs among these patients.

Read More

Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen

Improving Outcomes With Transplant in Myelodysplastic Syndromes

Improving Outcomes With Transplant in Myelodysplastic Syndromes

Jordyn Sava
September 19th 2024
Article

In an interview with Targeted Oncology, Sergio A. Giralt, MD, discussed the evolving role of transplant in myelodysplastic syndromes.

Read More

Dizman’s Global Pursuit to Cancer Research and Understanding

Dizman’s Global Pursuit to Cancer Research and Understanding

Jordyn Sava;Nazli Dizman, MD
April 1st 2024
Podcast

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Listen

Darolutamide Plus ADT Shows Efficacy and Safety Vs ADT Alone in mHSPC

Darolutamide Plus ADT Shows Efficacy and Safety Vs ADT Alone in mHSPC

Jonah Feldman
September 16th 2024
Article

The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without docetaxel in the metastatic hormone-sensitive prostate cancer setting.

Read More

Sequencing Matters: Giving Radium-223 Prior to Docetaxel Leads to Improved HRQOL, Tolerability in mCRPC

Sequencing Matters: Giving Radium-223 Prior to Docetaxel Leads to Improved HRQOL, Tolerability in mCRPC

Tony Berberabe, MPH
September 16th 2024
Article

The RAPSON trial found that receiving radium-223 prior to docetaxel in patients with metastatic castration-resistant prostate cancer improved quality of life and tolerability compared to the reverse sequence, without affecting progression-free survival or overall survival.

Read More